Compare Stocks: NKTX, SVA, AVTE, and MDXG

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$24.71 +3.8%	$20.08	$89.95 ▼ $99.05	$716.22M	0.95	53,591 shs	1.48 million shs
MDXG MiMedx Group	$4.27 +1.7%	$4.04	$3.03 ▼ $7.97	$622.40M	1.45	1.52 million shs	974,754 shs
NKTX Nkarta	$2.33 +1.3%	$2.64	$1.70 ▼ $3.72	$166.89M	0.93	630,695 shs	302,396 shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.66M	0.79	N/A	N/A

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	+3.78%	+12.52%	+13.04%	+5.80%	+234.37%
MDXG MiMedx Group	0.00%	-1.61%	-3.61%	+19.94%	-41.27%
NKTX Nkarta	0.00%	-3.32%	-10.38%	-11.74%	+5.43%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$24.71 +3.8%	$20.08	$89.95 ▼ $99.05	$716.22M	0.95	53,591 shs	1.48 million shs
MDXG MiMedx Group	$4.27 +1.7%	$4.04	$3.03 ▼ $7.97	$622.40M	1.45	1.52 million shs	974,754 shs
NKTX Nkarta	$2.33 +1.3%	$2.64	$1.70 ▼ $3.72	$166.89M	0.93	630,695 shs	302,396 shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.66M	0.79	N/A	N/A

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	+3.78%	+12.52%	+13.04%	+5.80%	+234.37%
MDXG MiMedx Group	0.00%	-1.61%	-3.61%	+19.94%	-41.27%
NKTX Nkarta	0.00%	-3.32%	-10.38%	-11.74%	+5.43%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
MDXG MiMedx Group	2.71	Moderate Buy	$8.50	99.06% Upside
NKTX Nkarta	2.86	Moderate Buy	$11.20	380.69% Upside
SVA Sinovac Biotech	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NKTX, SVA, AVTE, and MDXG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	NKTX Nkarta	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$11.00 ➝ $10.00
8/11/2026	NKTX Nkarta	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$14.00
6/24/2026	NKTX Nkarta	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/23/2026	NKTX Nkarta	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
5/18/2026	MDXG MiMedx Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
5/18/2026	NKTX Nkarta	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$9.00
5/18/2026	NKTX Nkarta	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
MDXG MiMedx Group	$418.63M	1.49	$0.55 per share	7.71	$1.48 per share	2.89
NKTX Nkarta	N/A	N/A	N/A	N/A	$3.46 per share	N/A
SVA Sinovac Biotech	$386.01M	1.67	$0.54 per share	11.89	$89.01 per share	0.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	N/A
MDXG MiMedx Group	$48.58M	$0.04	106.78	25.12	N/A	1.76%	12.09%	9.22%	11/4/2026 (Estimated)
NKTX Nkarta	-$104.08M	-$1.57	N/A	N/A	N/A	N/A	-39.64%	-30.45%	N/A
SVA Sinovac Biotech	-$59.68M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest NKTX, SVA, AVTE, and MDXG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/10/2026	Q2 2026	NKTX Nkarta	-$0.3603	-$0.54	-$0.1797	-$0.54	N/A	N/A
7/29/2026	Q2 2026 & M&A announcement	MDXG MiMedx Group	-$0.0495	-$0.05	-$0.0005	-$0.10	$63.46 million	$64.36 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
MDXG MiMedx Group	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A
SVA Sinovac Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTE Aerovate Therapeutics	N/A	8.78	8.78
MDXG MiMedx Group	0.07	5.33	4.79
NKTX Nkarta	N/A	7.98	12.96
SVA Sinovac Biotech	0.04	4.59	4.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTE Aerovate Therapeutics	N/A
MDXG MiMedx Group	79.15%
NKTX Nkarta	80.54%
SVA Sinovac Biotech	N/A

Insider Ownership

Company	Insider Ownership
AVTE Aerovate Therapeutics	24.90%
MDXG MiMedx Group	2.50%
NKTX Nkarta	9.80%
SVA Sinovac Biotech	12.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
MDXG MiMedx Group	870	145.76 million	142.12 million	Optionable
NKTX Nkarta	140	71.62 million	64.61 million	Optionable
SVA Sinovac Biotech	3,008	99.64 million	86.89 million	Optionable

NKTX, SVA, AVTE, and MDXG Headlines

Recent News About These Companies

Reviewing Sinovac Biotech (NASDAQ:SVA) & Burning Rock Biotech (NASDAQ:BNR)

August 13 at 4:15 AM | americanbankingnews.com

Sinovac Biotech Corporate Event Calendar | NASDAQ:SVA

July 21, 2026 | benzinga.com

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend

July 15, 2026 | businesswire.com

SINOVAC Board of Directors Alerts Shareholders to Advantech/Prime Success’ New Lawsuit, Which Threatens to Prevent Payment of US$55.00 Special Dividend to All Valid Shareholders

July 12, 2026 | businesswire.com

Sinovac Regains Nasdaq Listing Compliance After Filing Delayed Annual Report

June 15, 2026 | tipranks.com

Sinovac Biotech Ltd.

June 8, 2026 | edition.cnn.com

SINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-F

June 5, 2026 | businesswire.com

Sinovac Faces New Nasdaq Delisting Risk After Regaining Compliance

May 29, 2026 | tipranks.com

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report

May 29, 2026 | businesswire.com

SVA Share News Today

May 16, 2026 | uk.investing.com

SINOVAC Reports Unaudited First Half of 2025 Financial Results

May 8, 2026 | businesswire.com

Sinovac Biotech Delays Key Annual 20-F Filing

April 30, 2026 | tipranks.com

SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 2024

April 30, 2026 | businesswire.com

Clearwater Recovery Partners LLP Announces Cash Offer to Purchase Common Shares in Sinovac Biotech Ltd.

March 28, 2026 | tennessean.comT

Sinovac Controlling Shareholders Escape Investor Disclosure Suit

February 25, 2026 | news.bloomberglaw.comN

SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing

January 22, 2026 | businesswire.com

Sinovac Biotech receives Nasdaq notification regarding late filing of FY25

January 4, 2026 | msn.com

Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report

January 4, 2026 | financialpost.comF

SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement

January 4, 2026 | businesswire.com

Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report

January 4, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX, SVA, AVTE, and MDXG Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

$24.71 +0.90 (+3.78%)

As of 08/14/2026

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

MiMedx Group NASDAQ:MDXG

$4.27 +0.07 (+1.67%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$4.28 +0.02 (+0.35%)

As of 08/14/2026 07:37 PM Eastern

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Nkarta NASDAQ:NKTX

$2.33 +0.03 (+1.30%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$2.33 0.00 (0.00%)

As of 08/14/2026 07:36 PM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Sinovac Biotech NASDAQ:SVA

$6.47 0.00 (0.00%)

As of 08/14/2026

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NKTX, SVA, AVTE, and MDXG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NKTX, SVA, AVTE, and MDXG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NKTX, SVA, AVTE, and MDXG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX, SVA, AVTE, and MDXG Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

MiMedx Group NASDAQ:MDXG

Nkarta NASDAQ:NKTX

Sinovac Biotech NASDAQ:SVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NKTX, SVA, AVTE, and MDXG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NKTX, SVA, AVTE, and MDXG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NKTX, SVA, AVTE, and MDXG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX, SVA, AVTE, and MDXG Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

MiMedx Group NASDAQ:MDXG

Nkarta NASDAQ:NKTX

Sinovac Biotech NASDAQ:SVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools